Pharmacokinetics and toxicity of213Bi-labeled PAI2 in preclinical targeted alpha therapy for cancer

Cancer Biology and Therapy

Volumn 6, Issue 6, 2007, Pages 898-904

  Song, Emma Y ^a,b   Abbas Rizvi, Syed M ^a   Qu, Chang F ^a,b,c   Raja, Chand ^a   Brechbiel, Martin W ^d   Morgenstern, Alfred ^c   Apostolidis, Christos ^c   Allen, Barry J ^a,b  

^a ST GEORGE HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c JOINT RESEARCH CENTRE   (Italy)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

213Bismuth; Acute toxicity; Maximum tolerance dose; Pharmacokinetics; Plasminogen activator inhibitor 2 (PAI2); Radioimmunotherapy; radiation

Indexed keywords

2 (P ISOTHIOCYANATOBENZYL)CYCLOHEXY 1 PENTETIC ACID; CHELATING AGENT; CYCLIC PENTETIC ACID; LYSINE; PLASMINOGEN ACTIVATOR INHIBITOR 2; PLASMINOGEN ACTIVATOR INHIBITOR 2 BI 213; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; BISMUTH; RADIOISOTOPE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG STABILITY; FEMALE; KIDNEY DISEASE; KIDNEY TUBULE ABSORPTION; KIDNEY TUBULE NECROSIS; MAXIMUM TOLERATED DOSE; MOUSE; NEOPLASM; NONHUMAN; RADIATION INJURY; WEIGHT REDUCTION; ALPHA RADIATION; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; KIDNEY; METASTASIS; METHODOLOGY; ONCOLOGY; PATHOLOGY; RABBIT; RADIOIMMUNOTHERAPY; TIME;

ALPHA PARTICLES; ANIMALS; BISMUTH; CHELATING AGENTS; FEMALE; KIDNEY; MEDICAL ONCOLOGY; MICE; MICE, INBRED BALB C; NEOPLASM METASTASIS; PLASMINOGEN ACTIVATOR INHIBITOR 2; RABBITS; RADIOIMMUNOTHERAPY; RADIOISOTOPES; TIME FACTORS;

EID: 42449100411     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.6.6.4097     Document Type: Article

References (38)

1. Allen BJ, Blagojevic N. Alpha- and beta-emitting radiolanthanides in targeted cancer therapy: The potential role of terbium-149. Nucl Med Commun 1996; 17:40-7.
2. Ballangrud AM, Yang WH, Charlton DE, McDevitt MR, Hamacher KA, Panageas KS, Ma D, Bander NH, Scheinberg DA, Sgouros G. Response of LNCaP spheroids after treatment with an {{alpha}}-particle emitter (213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591). Cancer Res 2001; 61:2008-14.
3. Aurlien E, Larsen RH, Akabani G, Olsen DR, Zalutsky MR, Bruland OS. Exposure of human osteosarcoma and bone marrow cells to tumour-targeted alpha-particles and gamma-irradiation: Analysis of cell survival and microdosimetry. Int J Radiat Biol 2000; 76:1129-41.
4. Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cellular and Molecular Life Sciences 2000; 57:25-40.
5. Schmitt M, Wilhelm OG, Reuning U, Kruger A. The urokinase plasminogen activation system as a novel target for tumour therapy. Fibrinol Proteol 2000; 14:114-32.
6. Hang M, Ranson M, Saunders D, Liang X, Bunn C, Baker M. Pharmacokinetics and biodistribution of recombinant human plasminogen activator inhibitor type 2 (PAI-2) in control and tumour xenograft-bearing mice. Fibrinol Proteol 1998; 12:145-54.
7. Ranson M, Tian Z, Andronicos NM, Rizvi S, Allen BJ. In vitro cytotoxicity of bismuth-213 (213Bi)-labeled-plasminogen activator inhibitor type 2 (alpha-PAI-2) on human breast cancer cells. Breast Cancer Res Treat 2002; 71:149-59.
8. Li Y, Rizvi SMA, Ranson M, Allen BJ. 213Bi-PAI2 conjugate selectively induces apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal model. British Journal of Cancer 2002; 86:1197-203.
9. Song YJ, Qu CF, Rizvi SMA, Li Y, Robertson G, Raja C, Morgenstern A, Apostolidis C, Perkins AC, Allen BJ. Cytotoxicity of PAI2, C595 and Herceptin vectors labeled with the alpha-emitting radioisotope Bismuth-213 for ovarian cancer cell monolayers and clusters. Cancer Letters 2006; 234:176-83.
10. Allen BJ, Tian Z, Rizvi SM, Li Y, Ranson M. Preclinical studies of targeted alpha therapy for breast cancer using 213Bi-labelled-plasminogen activator inhibitor type 2. Br J Cancer 2003; 88:944-50.
11. Qu CF, Song EY, Li Y, Rizvi SM, Raja C, Smith R, Morgenstern A, Apostolidis C, Allen BJ. Preclinical study of (213)Bi labeled PAI2 for the control of micrometastatic pancreatic cancer. Clin Exp Metastasis 2005; 22:575-86.
12. Zidenberg-Cherr S, Parks NJ, Keen CL. Tissue and subcellular distribution of bismuth radiotracer in the rat: Considerations of cytotoxicity and microdosimetry for bismuth radiopharmaceuticals. Radiat Res 1987; 111:119-29.
13. Yao Z, Zhang M, Garmestani K, Axworthy DB, Mallett RW, Fritzberg AR, Theodore LJ, Plascjak PS, Eckelman WC, Waldmann TA, Pastan I, Paik CH, Brechbiel MW, Carrasquillo JA. Pretargeted alpha emitting radioimmunotherapy using (213)Bi 1,4,7,10-tetraazacyclododecane-N, N′,N″,N‴- tetraacetic acid-biotin. Clin Cancer Res 2004; 10:3137-46.
14. Behr TM, Boerman OC. 13th Meeting of the international research group on immunoscintigraphy and immunotherapy (IRIST): 7-8 May 1999, Gottingen, Germany. Eur J Nucl Med 1999; 26:950-2.
15. Norenberg JP, Krenning BJ, Konings IRHM, Kusewitt DF, Nayak TK, Anderson TL, de Jong M, Garmestani K, Brechbiel MW, Kvols LK. 213Bi-[DOTA0, Tyr3]Octreotide peptide receptor radionuclide therapy of pancreatic tumors in a preclinical animal model. Clin Cancer Res 2006; 12:897-903.
16. Cohen EP. Nephritis, radiation. In: Mulloy LL, Talavera F, Batuman V, eds. Nephrology: Emedicine, 2005.
17. Madrazo A, Schwarz G, Churg J. Radiation nephritis: A review. Journal of Urology 1975; 114:822-7.
18. Mogensen CE, Solling. Studies on renal tubular protein reabsorption: Partial and near complete inhibition by certain amino acids. Scandinavian Journal of Clinical and Laboratory Investigation 1977; 37:477-86.
19. Arano Y, Fujioka Y, Akizawa H, Ono M, Uehara T, Wakisaka K, Nakayama M, Sakahara H, Konishi J, Saji H. Chemical design of radiolabeled antibody fragments for low renal radioactivity levels. Cancer Research 1999; 59:128-34.
20. Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: Present status, future prospects and limitations. European Journal of Nuclear Medicine 1998; 25:201-12.
21. Jaggi JS, Kappel BJ, McDevitt MR, Sgouros G, Flombaum CD, Cabassa C, Scheinberg DA. Efforts to control the errant products of a targeted in vivo generator. Cancer Res 2005; 65:4888-95.
22. Rizvi SM, Sarkar S, Goozee G, Allen BJ. Radioimmunoconjugates for targeted alpha therapy of malignant melanoma. Melanoma Res 2000; 10:281-9.
23. Apostolidis C, Molinet R, Rasmussen G, Morgenstern A. Production of Ac-225 from Th-229 for targeted alpha therapy. Anal Chem 2005; 77:6288-91.
24. Bernard BF, Krenning EP, Breeman WA, Rolleman EJ, Bakker WH, Visser TJ, Macke H, de Jong M. D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake. Journal of Nuclear Medicine 1997; 38:1929-33.
25. Behr TM, Sharkey RM, Sgouros G, Blumenthal RD, Dunn RM, Kolbert K, Griffiths GL, Siegel JA, Becker WS, Goldenberg DM. Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: Improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry. Cancer 1997; 80:2591-610.
26. Loevinger R, Berman M. A schema for absorbed dose calcualtions for biological distributed radionuclides. J Nucl Med 1968; 9:7-9.
27. Rizvi SM, Li Y, Jun Song EY, Qu CF, Raja C, Morgenstern A, Apostolidis C, Allen BJ. Preclinical studies of bismuth-213 labeled plasminogen activator inhibitor type 2 (PAI2) in a prostate cancer nude mouse xenograft model. Cancer Biol Ther 2006; 5:386-93.
28. Allen BJ, Raja C, Rizvi S, Li Y, Tsui W, Zhang D, Song E, Qu CF, Kearsley J, Graham P, Thompson J. Targeted alpha therapy for cancer. Phys Med Biol 2004; 49:3703-12.
29. Bethge WA, Wilbur DS, Storb R, Hamlin DK, Santos EB, Brechbiel MW, Fisher DR, Sandmaier BM. Selective T-cell ablation with bismuth-213-labeled anti-TCR{alpha}{beta} as nonmyeloablative conditioning for allogeneic canine marrow transplantation. Blood 2003; 101:5068-75.
30. Slikkerveer A, Jong HB, Helmich RB, de Wolff FA. Development of a therapeutic procedure for bismuth intoxication with chelating agents. Journal of Laboratory and Clinical Medicine 1992; 119:529-37.
31. Russ GA, Bigler R, Tilbury R, Woodard H, Laughlin J. Metabolic studies with radiobismuth. I. Retention and distribution of 206Bi in the normal rat. Radiat Res 1975; 63:443-54.
32. Guyton C. Textbook of medical physiology. W.B. Saunders, 1991.
33. Nikulina K, Patel-King RS, Takebe S, Pfister KK, King SM. The Roadblock light chains are ubiquitous components of cytoplasmic dynein that form homo- and heterodimers. Cell Motil Cytoskeleton 2004; 57:233-45.
34. Seidl C, Schrock H, Seidenschwang S, Beck R, Schmid E, Abend M, Becker KF, Apostolidis C, Nikula TK, Kremmer E, Schwaiger M, Senekowitsch-Schmidtke R. Cell death triggered by alpha-emitting 213Bi-immunoconjugates in HSC45-M2 gastric cancer cells is different from apoptotic cell death. Eur J Nucl Med Mol Imaging 2005; 32:274-85.
35. Milenic DE, Roselli M, Mirzadeh S, Pippin CG, Gansow OA, Colcher D, Brechbiel MW, Schlom J. In vivo evaluation of bismuth-labeled monoclonal antibody comparing DTPA-derived bifunctional chelates. Cancer Biotherapy and Radiopharmaceuticals 2001; 16:133-46.
36. Roselli M, Milenic DE, Brechbiel MW, Mirzadeh S, Pippin CG, Gansow OA, Colcher D, Schlom J. In vivo comparison of CHX-DTPA ligand isomers in athymic mice bearing carcinoma xenografts. Cancer Biotherapy and Radiopharmaceuticals 1999; 14:209-20.
37. Jaggi JS, Seshan SV, McDevitt MR, LaPerle K, Sgouros G, Scheinberg DA. Renal tubulointerstitial changes after internal irradiation with {alpha}-particle-emitting actinium daughters. J Am Soc Nephrol 2005; 16:2677-89.
38. Pearse H. The kidney. In: JD C, ed. Moss' radiation oncology: Rationale, technique, results. St. Louis: Mosby, 1994:499-517.